Form 4: Director Robert A. Lenz Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Robert A. Lenz of LB Pharmaceuticals Inc. was granted 12,500 stock options as part of the company's director compensation policy.
Summary
- Director Robert A. Lenz was granted 12,500 stock options on June 3, 2026.
- The options have an exercise price of $27.95 per share.
- The grant includes a prorated annual award of 2,500 shares for the previous year.
- The options are set to expire on June 2, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Vesting is contingent upon the reporting person's continuous service through the vesting date.
Future Outlook
The options vest on the earlier of June 3, 2027, or the date of the next annual meeting of stockholders, provided the director remains in service.
Management Comments
- The grant is consistent with the Issuer's non-employee director compensation policy.
Industry Context
StockSavvy.ai notes that equity grants for non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with long-term corporate performance.
Comparison to Industry Standards
- The use of time-based vesting for director options is consistent with standard corporate governance practices for small-cap biotech firms.
- The inclusion of a prorated annual grant is a common mechanism to address compensation timing gaps for board members.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Issuance of stock options under the existing non-employee director compensation policy. | 06/03/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 3, 2027, or the next annual meeting date.
Key Dates
| Date | Description |
|---|---|
| 06/03/2026 | Date of the stock option grant transaction. |
| 06/03/2027 | Vesting date for the granted options (or the date of the next annual meeting). |
| 06/02/2036 | Expiration date of the stock options. |
Keywords
LB Pharmaceuticals, LBRX, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.